Welcome to our dedicated page for Alkermes news (Ticker: ALKS), a resource for investors and traders seeking the latest updates and insights on Alkermes stock.
Alkermes plc develops and commercializes neuroscience medicines, with proprietary commercial products used in alcohol dependence, opioid dependence, schizophrenia, bipolar I disorder and narcolepsy. Company news commonly covers quarterly financial results, full-year expectations, commercial execution and presentations at healthcare and CNS investor conferences.
Clinical and medical updates focus on the company’s sleep-wake and psychiatric portfolio, including LYBALVI in schizophrenia and bipolar I disorder and alixorexton, an investigational oral selective orexin 2 receptor agonist in development for narcolepsy and idiopathic hypersomnia. Other updates include peer-reviewed data publications, research award programs and corporate developments tied to Alkermes’ biopharmaceutical operations.
Alkermes plc (Nasdaq: ALKS) has announced the launch of its 7th Annual Alkermes Pathways Research Awards® program, set to begin accepting applications on Sept. 20, 2024. This competitive grant program offers individual grants of up to $100,000 per project to support early-career investigators researching schizophrenia or bipolar disorder. The application period runs through Nov. 30, 2024.
Since its inception in 2018, the program has provided approximately $2.5 million in funding to 25 researchers across the United States. Eligible applicants must be M.D.s, Ph.D.s, or equivalent, within five years of their initial academic appointment or current post-doctoral fellows affiliated with a U.S. medical or research institution. An independent review committee will evaluate applications.
Alkermes plc (Nasdaq: ALKS), a global biopharmaceutical company specializing in neuroscience, has announced its participation in the Morgan Stanley 22nd Annual Global Healthcare Conference. The company's management will engage in a fireside chat presentation on Wednesday, Sept. 4, 2024, at 2:35 p.m. EDT. Investors can access the live webcast on Alkermes' website under the Investors tab, where it will remain archived for 14 days.
Alkermes focuses on developing innovative medicines for neurological disorders, with a portfolio of commercial products treating conditions such as alcohol dependence, opioid dependence, schizophrenia, and bipolar I disorder. The company also has a pipeline of clinical and preclinical candidates for various neurological disorders, including narcolepsy. Headquartered in Ireland, Alkermes maintains a corporate office and research center in Massachusetts and a manufacturing facility in Ohio.
Alkermes plc (Nasdaq: ALKS) has initiated the Vibrance-2 study, a phase 2 clinical trial evaluating ALKS 2680 for the treatment of narcolepsy type 2 (NT2). ALKS 2680 is a novel, oral, selective orexin 2 receptor agonist being developed as a once-daily treatment for narcolepsy. The study will assess the safety and efficacy of ALKS 2680 compared to placebo in adults with NT2.
The trial will enroll approximately 80 patients across sites in the U.S., Australia, and Europe. Participants will receive one of three doses of ALKS 2680 (10 mg, 14 mg, or 18 mg) or placebo once-daily for eight weeks. The primary endpoint will measure changes in sleepiness using the maintenance of wakefulness test (MWT).
Alkermes plc reported strong Q2 2024 financial results, with total revenues of $399.1 million. Net sales of proprietary products increased 16% year-over-year. The company achieved GAAP net income from continuing operations of $94.7 million and diluted GAAP earnings per share of $0.55. Key highlights include:
- LYBALVI revenues grew 52% to $71.4 million
- ARISTADA revenues reached $86.0 million
- VIVITROL revenues increased 10% to $111.9 million
- Cash position strengthened to $962.5 million
Alkermes reiterated its 2024 financial guidance and reported progress on its neuroscience pipeline, including positive results for ALKS 2680 in narcolepsy studies. The company remains focused on driving commercial performance and advancing its development programs.
Alkermes plc (Nasdaq: ALKS) has announced it will host a conference call and webcast on July 24, 2024, at 8:00 a.m. ET to discuss its second quarter financial results. The event will be accessible via the Investors section of Alkermes' website, with a replay available approximately two hours after completion. U.S. callers can dial +1 877 407 2988, while international callers should use +1 201 389 0923 to access the conference call.
Alkermes is a global biopharmaceutical company focused on developing innovative medicines in neuroscience. The company has commercial products for alcohol dependence, opioid dependence, schizophrenia, and bipolar I disorder, as well as a pipeline of candidates for neurological disorders, including narcolepsy.
Alkermes revealed data from a Phase 1b study of ALKS 2680, a novel orexin 2 receptor agonist, showing significant improvements in wakefulness in patients with narcolepsy type 1 (NT1). The study, presented at SLEEP 2024, demonstrated that ALKS 2680 significantly improved mean sleep latency compared to placebo across all doses. The drug was well-tolerated, with most adverse events being mild and transient. Additionally, the ongoing Phase 2 Vibrance-1 study will further evaluate the efficacy and safety of ALKS 2680 in NT1 patients. Initial results are encouraging, highlighting the potential of ALKS 2680 to address unmet needs in NT1 treatment.
Alkermes (Nasdaq: ALKS) announced its participation in two upcoming investor conferences. Management will present at the Jefferies Healthcare Conference on June 6, 2024, at 1:30 p.m. EDT and at the Goldman Sachs 45th Annual Global Healthcare Conference on June 11, 2024, at 10:40 a.m. EDT. The presentations will be webcast live and available under the Investors tab on Alkermes' website for 14 days. Alkermes is a biopharmaceutical company with a portfolio targeting alcohol and opioid dependence, schizophrenia, and bipolar I disorder, along with a pipeline for neurological disorders.
Alkermes announced plans to present three posters on ALKS 2680, a novel, investigational, oral orexin 2 receptor agonist, at SLEEP 2024, June 1-5 in Houston.
Key presentations include:
- Data from a phase 1b study of ALKS 2680 in narcolepsy type 1 (NT1) patients, evaluating safety and efficacy.
- Study design and methods for the Vibrance-1 phase 2 trial comparing ALKS 2680 with placebo in NT1 patients.
- Findings from interviews on the impact of narcolepsy on patients' lives.
Significant progress has been noted in the ALKS 2680 program, with proof-of-concept data validating the design hypothesis and initiating the Vibrance-1 phase 2 study.
Alkermes (Nasdaq: ALKS) announced the presentation of research related to its psychiatry franchise products, LYBALVI and ARISTADA, at four scientific conferences in Spring 2024. These conferences, held during Mental Health Awareness Month, include events like the APA Annual Meeting and ASCP Annual Meeting.
Key highlights include results from a long-term phase 3 study on LYBALVI's safety and efficacy and insights from healthcare resource utilization studies on ARISTADA. Alkermes aims to advance understanding and evidence for their psychiatric treatments targeting schizophrenia and bipolar I disorder.
Alkermes plc has completed the sale of its development and manufacturing facility in Athlone, Ireland to Novo Nordisk for approximately $91 million. The sale is part of Alkermes' program to drive operational efficiency and align its infrastructure with business needs. The transaction includes a subcontracting agreement with Novo Nordisk until the end of 2025, expected to be cost-neutral to Alkermes. Post-subcontracting, the sale is anticipated to provide significant operating cost benefits and enhance profitability. Alkermes will retain royalty revenues from products manufactured at the facility while continuing to produce its commercial products in Ohio.